Between the Lines™ Podcast: Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC
Gregory Riely, MD, PhD, and Tarek Mekhail, MD, detailed the use of mobocertinib of platinum-pretreated patients with metastatic non–small cell lung cancer.
Between the Lines™ Podcast: Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC
As part of its OncView™ video series, CancerNetwork® spoke with Gregory Riely, MD, PhD, vice chair of Clinical Research in the Department of Medicine at Memorial Sloan Kettering Cancer Center in New York, and Tarek Mekhail, MD, a hematologic oncologist from Advent Health in Florida, about patients with EGFR exon 20 insertion-positive metastatic non–small cell lung cancer who recieved mobocertinib.
In the video series, Gregory Riely, MD, PhD, and Tarek Mekhail, MD, discussed the following:
- Mobocertinib Use in mNSCLC: EXCLAIM Cohort Study Design
- Efficacy Data From the EXCLAIM Cohort in mNSCLC
- EXCLAIM Cohort: Mobocertinib Safety Data in mNSCLC
- EXCLAIM Cohort in mNSCLC: Treatment Selection and Management
- mNSCLC: Biomarker Testing and Patient Adherence to TKIs
- Next Steps in the Management of EGFR Exon 20 Insertion–Positive mNSCLC
To watch more videos in the CancerNetwork® Between the Lines™ series, visit cancernetwork.com/oncview.
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
